Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELITE
NCT00114517Phase 2Completed
- Sponsor
- University of Southern California
- Start
- Jul 2004
- Primary completion
- Feb 2013
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerosis and No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity comparing 17B-estradiol with Placebo (2 arms). Primary endpoint: Progression of Subclinical Atherosclerosis (Carotid Intima-Media Thickness). Started Jul 2004; status: completed.
02
Drugs
estradiol
03
Conditions
atherosclerosisNo canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT00114517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114517.